PREVIOUS
✖
First Indigenous CAR T-Cell Therapy in India
November 12 , 2025
15 hrs 0 min
10
0
- The NexCAR19, India’s first indigenous Chimeric Antigen Receptor (CAR) T-cell therapy was launched recently.
- The therapy targets B-cell blood cancers, including leukemia and lymphoma.
- NexCAR19 is developed by Immuno ACT, an IIT Bombay-incubated startup, in collaboration with Tata Memorial Hospital.
- CAR T-cell therapy uses a patient’s own T-cells, genetically modified to attack cancer cells, and then reinfused into the body.
Leave a Reply
Your Comment is awaiting moderation.